Hepatitis Screening and Treatment Campaign in Malaysia- Validation of Low-cost Point of Care Screening Tests and Nucleic Acid Tests for Hepatitis B and C

M, Radzi Ah; Mohamed, Rosmawati; Jaya, Fauziah; Abdullah, Rafidah; M, Al Mahtab; Morad, Zaki; To, Lim

doi:10.5005/jp-journals-10018-1273

Cited by 5 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The civil society organizations (CSOs) played an active role in increasing the screening uptake among high-risk groups, particularly persons who inject drugs and persons living with HIV. Multi-organizational participation is of great significance in pushing the agenda of hepatitis C elimination in Malaysia [50] , [51] , [52] .…”

Section: Strategic Responses-success Of Malaysia and Efforts Made In Chinamentioning

confidence: 99%

What China can learn from Malaysia to achieve the goal of “eliminate hepatitis C as a public health threat” by 2030 – a narrative review

Sun

Cheng

Hassan

et al. 2021

The Lancet Regional Health - Western Pacific

View full text Add to dashboard Cite

Background: To discuss a range of strategic options for China to improve the accessibility of direct antiviral agents (DAAs) as the treatment for hepatitis C. Methods: We adopted a narrative review approach for comprehensive comparisons and in-depth analyses of the country context, and barriers of increasing the DAA treatment rate of hepatitis C in Malaysia and China, and how the two countries have been navigating the hepatitis C agenda. Findings: Malaysia adopted a series of successful strategies to scale up the diagnosis of hepatitis C and DAA treatment, which have valuable implications for China. Interpretation: The potential game-changing strategies for China to adapt from Malaysian experiences range from the stepping-up of political commitment and leadership, enhanced market competition, simplified and decentralized treatment at the strengthened primary care level, integrated healthcare services, coordinated government initiatives, to multi-organizational participation and civil society's active role in raising public awareness, and training of non-specialist physicians. Embarking on scale-up of hepatitis C treatment marks another contribution of China to improve the health of not only the Chinese citizens but also mankind, which is an important component for building healthy Chinese and global communities. Funding: No funding supported this study.

show abstract

Section: Strategic Responses-success Of Malaysia and Efforts Made In Chinamentioning

confidence: 99%

What China can learn from Malaysia to achieve the goal of “eliminate hepatitis C as a public health threat” by 2030 – a narrative review

Sun

Cheng

Hassan

et al. 2021

The Lancet Regional Health - Western Pacific

View full text Add to dashboard Cite

show abstract

Prevalence of Chronic Hepatitis B and C in Malaysia- results from a community-based screening campaign

Lim¹,

Teo²,

Tan³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Introduction The epidemiology of hepatitis, which is apparently endemic in Asia, is still poorly documented in Malaysia. Available statistics are modelled estimates based on expert input or estimated from small studies on special populations. We therefore determined the prevalence of chronic hepatitis B and C in Malaysia based on a large sample data from a screening campaign. Methods A total of 10,914 subjects participated in the hepatitis screening campaign in 2018 and 2019. A low-cost Point-of-care test, which has previously been validated, was used to screen for HBsAg and anti-HCV. All screen positive subjects were recalled to undergo confirmatory serology tests and nucleic acid tests. Results We estimated 1.17% or 238,971 Malaysian adults aged 20 or older had chronic HBV, while only 0.74% or 151,144 adults had chronic HCV. Young adults below age 30 years had very low prevalence of HBV (0.09%). Women had lower prevalence of HBV and HCV, Chinese had the highest prevalence of HBV while Malay had the highest prevalence of HCV. Conclusion Young adults seems to be protected from HBV perhaps owing to the introduction of universal HBV vaccination since 1989. Chronic HBV however remains prevalent in older adults especially among the Chinese. Chronic HCV is uncommon in Malaysia.

show abstract

Cascade of care, awareness and treatment of Chronic Hepatitis B in Malaysia- findings from a community-based screening campaign

Lim¹,

Teo²,

Tan³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Introduction In 2016 the World Health Organization (WHO) had adopted a global strategy to eliminate Hepatitis B (HBV) by 2030 through five core interventions, the first four were preventive while the fifth is the cascade of care, the continuum of services that persons with chronic HBV should receive as they progress from screening to diagnosis to treatment to chronic care. We determined the prevalence of the awareness and treatment of chronic HBV in Malaysia based on a large sample data from a screening campaign. Methods A total of 10,436 subjects participated in the HBV screening campaign organized by the Hepatitis Free Pahang Malaysia (HFPM) in 2018 and 2019. All screen-positive subjects were recalled to undergo laboratory-based HBsAg and HBV DNA tests. Patients with confirmed chronic HBV were referred to local health services, while continued being monitored by HFPM. Results We estimated 13.1% of Malaysian adults aged 20 or older with chronic HBV were aware of their HBV status, and of those only 0.7% had received prior anti-viral treatment, but among those with baseline HBV DNA level>20,000 IU/ml, 15.6% were subsequently treated. Tenofovir disoproxil fumarate was the only medicine used on all treated patients. The linkage to care post-screening was broken in substantial number of patients, only 108 (54%) subjects had returned to have their HBV DNA measured and only 115 (58%) patients had subsequently sought care and were on still follow-up. Conclusion Few Malaysian adults with HBV were aware of their infection and even less received anti-viral therapy. Concerted public health efforts are urgently needed to improve HBV screening and care cascade in order to meet WHO targets for HBV elimination. Keywords Cascade of care, Awareness, Treatment, Hepatitis B, Malaysia

show abstract

Hepatitis Screening and Treatment Campaign in Malaysia- Validation of Low-cost Point of Care Screening Tests and Nucleic Acid Tests for Hepatitis B and C

Cited by 5 publications

References 18 publications

What China can learn from Malaysia to achieve the goal of “eliminate hepatitis C as a public health threat” by 2030 – a narrative review

What China can learn from Malaysia to achieve the goal of “eliminate hepatitis C as a public health threat” by 2030 – a narrative review

Prevalence of Chronic Hepatitis B and C in Malaysia- results from a community-based screening campaign

Cascade of care, awareness and treatment of Chronic Hepatitis B in Malaysia- findings from a community-based screening campaign

Contact Info

Product

Resources

About